- Conditions
- Kidney Diseases
- Interventions
- Anti-thymocyte globulin, Mycophenolate mofetil, Prednisone, Tacrolimus, Sirolimus
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 37
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
- Interventions
- Alemtuzumab, Tacrolimus, Mycophenolate mofetil, Sirolimus
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Year to 20 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 4
- States / cities
- San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
- Conditions
- Renal Transplant
- Interventions
- Belatacept, Sirolimus, Anti-thymocyte globulin, methylprednisolone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- San Francisco, California • Atlanta, Georgia
- Conditions
- Kidney Transplant Recipient
- Interventions
- Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
- Biological · Other
- Lead sponsor
- Mark Stegall
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Kidney Failure, Renal Failure
- Interventions
- Tacrolimus (Tacro™), Prograf
- Drug
- Lead sponsor
- Veloxis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Allergies, Allergic Rhinitis, Asthma
- Interventions
- sublingual immunotherapy, placebo sublingual immunotherapy
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Orthotopic Liver Transplant
- Interventions
- Everolimus, Standard Tacrolimus
- Drug
- Lead sponsor
- Tomoaki Kato
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Kidney Transplant
- Interventions
- Everolimus and tacrolimus, mycophenolate mofetil and tacrolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 39 more
- Conditions
- Amputation, Traumatic
- Interventions
- Hand Transplantation
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Liver Transplantation
- Interventions
- tacrolimus, mycophenolate mofetil, Prednisone
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Kidney Failure, Chronic
- Interventions
- Everolimus
- Drug
- Lead sponsor
- Ashtar Chami
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Graft-versus-host-disease, GVHD, GVHD, Acute
- Interventions
- BMS-986004, Sirolimus, Tacrolimus
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- Duarte, California • Tampa, Florida • Columbus, Ohio
- Conditions
- Heart Transplantation, Liver Transplantation, Kidney Transplantation
- Interventions
- FK506E
- Drug
- Lead sponsor
- Astellas Pharma Europe Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant, Living Kidney Donor
- Interventions
- Polyclonal Regulatory T Cells, Everolimus, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid, Acetaminophen, Diphenhydramine, Biopsy, Kidney, Blood Draw, Leukapheresis, IS regimen conversion
- Biological · Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Clotrimazole, Valganciclovir, Heparin, Enoxaparin, Pentoxifylline, Aspirin
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Facial Injuries, Traumatic Wounds and Injuries, Craniofacial Injuries, Craniofacial Defects, Facial Transplantation, Facial Deformity
- Interventions
- Bone marrow cell-based therapy & 1-drug immunosuppression.
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2041
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Transplanted Organ Rejection
- Interventions
- FCR001
- Biological
- Lead sponsor
- Talaris Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • La Jolla, California • San Francisco, California + 14 more
- Conditions
- Frontotemporal Dementia
- Interventions
- LY3884963, Methylprednisolone, Optional Sirolimus, Optional Prednisone
- Biological · Drug
- Lead sponsor
- Prevail Therapeutics
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 4
- States / cities
- Maitland, Florida • Orlando, Florida • Burlington, Massachusetts + 1 more
- Conditions
- Graft Rejection, Kidney Disease
- Interventions
- Alemtuzumab and DSG
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Liver Transplantation
- Interventions
- tacrolimus modified release (MR), tacrolimus
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 10
- States / cities
- Palo Alto, California • Denver, Colorado • Baltimore, Maryland + 7 more
- Conditions
- Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
- Interventions
- calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids, immunosuppression withdrawal
- Drug · Procedure · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 8
- States / cities
- San Francisco, California • Denver, Colorado • Chicago, Illinois + 5 more
- Conditions
- Vitiligo
- Interventions
- Rapamycin, Placebo
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Liver Failure
- Interventions
- LCP -Tacro, Prograf
- Drug
- Lead sponsor
- Veloxis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Kidney Transplantation, Chronic Kidney Failure
- Interventions
- efalizumab
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia